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Abstract: Liver inflammation contributes towards the pathology of non-alcoholic fatty liver 
disease (NAFLD). Here we discuss how skin exposure to sunlight may suppress liver 
inflammation and the severity of NAFLD. Following exposure to sunlight-derived 
ultraviolet radiation (UVR), the skin releases anti-inflammatory mediators such as vitamin 
D and nitric oxide. Animal modeling studies suggest that exposure to UVR can prevent the 
development of NAFLD. Association studies also support a negative link between 
circulating 25-hydroxyvitamin D and NAFLD incidence or severity. Clinical trials are in 
their infancy and are yet to demonstrate a clear beneficial effect of vitamin D 
supplementation. There are a number of potentially interdependent mechanisms whereby 
vitamin D could dampen liver inflammation, by inhibiting hepatocyte apoptosis and liver 
fibrosis, modulating the gut microbiome and through altered production and transport of bile 
acids. While there has been a focus on vitamin D, other mediators induced by sun exposure, 
such as nitric oxide may also play important roles in curtailing liver inflammation.  
Keywords: sunlight; vitamin D; nitric oxide; liver; inflammation; non-alcoholic fatty  
liver disease 
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1. What Is Non-Alcoholic Fatty Liver Disease? 
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disorders ranging from simple steatosis 
to non-alcoholic steatohepatitis. NAFLD is linked with obesity, type-2 diabetes and metabolic syndrome, 
and is now the most prevalent liver disorder in western countries. It is caused by excessive accumulation 
of fat (triglycerides) in the liver [1] and results in abnormal lipid metabolism, but the underlying 
molecular mechanisms are under debate [2,3]. In the double-hit hypothesis, lipid accumulation in the 
liver is followed by the release of pro-inflammatory mediators that induce inflammation, hepatocyte 
death and fibrosis [4]. Others suggest that free fatty acids and cytokines (such as tumour necrosis factor-α, 
TNFα) are hepatotoxic and underpin the molecular pathogenesis of NAFLD [5]. A third hypothesises is 
that multiple hits are required, including genetic, environmental and nutritional factors, involving diverse 
parallel processes including fatty acids, bacterial lipopolysaccharides, cytokines, chemokines and 
adipokines, which acting in concert induce NAFLD [6,7]. Here we discuss the evidence for sunlight-derived 
mediators, such as vitamin D and nitric oxide (NO) in suppressing hepatic inflammation that contributes 
towards the severity of NAFLD. 
2. Sunlight-Derived Ultraviolet Radiation—A Systemic Modulator of Inflammation 
Ultraviolet radiation (UVR) derived from the sun has both local and systemic effects on health. Skin 
exposure to UVR induces several immune effector molecules, including vitamin D, NO, heme 
oxygenase, cis-urocanic acid and serotonin (Figure 1, reviewed in [8]). The UVR spectrum is divided 
into three distinct biologically active wavelength bands: UVA (315–400 nm), UVB (280–315 nm) and 
UVC (100–280 nm); and, since the latter does not penetrate the ozone layer of the atmosphere it will not 
be discussed here. UVB is largely absorbed in the epidermis while around 30% of UVA reaches the 
dermis. Here, we discuss the roles of vitamin D, NO and heme oxygenase as immune and inflammatory 
modulators induced by UVR. 
Vitamin D3 is formed when 7-dehydrocholesterol in skin cells, predominantly keratinocytes, absorb 
UVB photons. Upon binding to vitamin D binding protein, vitamin D circulates to the liver for 
hydroxylation at the 25-position (to form 25(OH)D) and subsequently to the kidney for hydroxylation 
to form active, but short-lived, 1,25-dihydroxyvitamin D (1,25(OH)2D)(Figure 1). The half-life of 
25(OH)D is 30–40 days so this is recognized as the storage circulating form. We have recently reviewed 
the effects of vitamin D on the immune system [9,10]. Most immune cells (and epithelial cells), express 
the inducible enzyme, CYP27B1 (1α-hydroxylase), so they too can make 1,25(OH)2D, and to high levels 
(up to 1 nM) for autocrine and paracrine effects at the local tissue level [11]. Innate immunity is our first 
line of defense against microbes, and macrophages and dendritic cells of the innate system can be 
activated through pathogen-recognition molecules (e.g., Toll-like receptors or NOD receptors) to 
increase CYP27B1 expression and thus, 1,25(OH)2D production. As all immune cells express the 
vitamin D receptor (VDR), 1,25(OH)2D may have autocrine effects to limit immune cell activation and 
inflammation. Other studies suggest that expression of the VDR is reduced by macrophage 
differentiation, providing a limit on the potential for these cells to respond to 1,25(OH)2D (reviewed  
by [12]). In the liver, VDR expression is mainly detected on non-hepatocytes, including sinusoidal 
epithelial cells, Kupffer cells, and particularly hepatic stellate cells, suggesting that they (and not 
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hepatocytes) harbour the capacity to respond quickly to local synthesis of 1,25(OH)2D [13]. Similarly 
other components of the vitamin D unit (including enzymes that inactivate 1,25(OH)2D; e.g., CYP24A1) 
may be regulated in response to immune activation (reviewed in [9]). The adaptive immune system is 
also modulated by 1,25(OH)2D, by inhibiting the activation of dendritic cells, decreasing cytokine 
production and suppressed T cell activation, and promoting the development of regulatory T cells. 
 
Figure 1. Skin exposure to ultraviolet (UV) photons from sunlight results in the synthesis of 
effector molecules that modulate immune and metabolic processes. These include: skin 
release of nitric oxide (NO), increasing serum levels of nitrite; initiation of the conversion of 
precursor molecules such as reactive oxygen species (ROS), trans-urocanic acid (UCA) and  
7-dehydrocholesterol (7-DHC) into platelet-activating factor, cis-UCA and 1,25-
dihydroxyvitamin D (1,25(OH)2D, calcitriol), respectively; and, the release of heme 
oxygenase, neuropeptides and neurohormones (e.g., α-melanocyte stimulating hormone  
(α-MSH), nerve growth factor (NGF)), immunoregulatory (interleukin(IL)s-4 and -10) and 
pro-inflammatory (tumor necrosis factor-α, IL-1α, prostaglandins) cytokines. Sun exposure 
of the skin results in systemic production of active vitamin D (1,25(OH)2D) through 
hydroxylation of vitamin D in the liver and 25-hydroxyvitamin D (25(OH)D) in the kidneys. 
These events can also occur locally in skin and immune cells that express the  
hydroxylating enzymes. 
NO can be formed by two independent mechanisms: production from L-arginine via the NO synthase 
(NOS) family of enzymes (neuronal NOS or NOS-I, inducible NOS or NOS-II, and endothelial NOS or 
NOS-III), and the serial reduction of nitrate (NO3−) to nitrite (NO2−) and then to NO. These activities are 
carried out by a multitude of enzyme systems and are oxygen dependent, although while NOS requires 
oxygen to form NO, the nitrate reduction pathway is inhibited by its presence. In addition to these 
enzymatic formation routes NO can also be released from preformed storage forms by light. The 
mechanisms of release by skin exposure to UVA radiation are discussed below. UVA and UVB radiation 
induces NOS-II and III expression in murine skin [14,15]. NO constitutively produced from eNOS limits 
keratinocyte apoptosis in a cGMP-dependent manner, which may thus ‘harden’ the skin against 
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premature apoptosis due to sun exposure. In humans, applying the NOS antagonist N(G)-monomethyl-
L-arginine to the skin prevented UVA-induced immunosuppression to a recall antigen, and depletion of 
epidermal Langerhans cells, the antigen-presenting cells of the epidermis [15]. 
Heme oxygenase (HO)-1 is an enzyme that catalyses the degradation of heme, and is typically 
produced in response to oxidative stress. Heme degradation is associated with the formation of carbon 
monoxide (CO) and biliverdin; CO can inhibit the production of pro-inflammatory cytokines while 
biliverdin acts as an antioxidant [16]. HO-1 may play a cytoprotective role in the skin following exposure 
to sunlight. It is induced in skin by exposure to UVA radiation, where it acts as an antioxidant [17]. 
UVA-induced HO-1 may reduce the ability of UVB radiation to suppress immune responses through  
IL-6 and estrogen receptor-β-dependent mechanisms [18,19]. 
3. Hepatic Inflammation Linked with NAFLD 
Chronic and/or excessive liver inflammation exacerbates the severity of NAFLD by killing  
hepatocytes [20]. Myofibroblasts replace dead hepatocytes, hindering liver function through fibrosis [21]. 
Hepatocyte death may be caused by profound mitochondrial dysfunction [22], the expression of 
extracellular signals that promote cell death (e.g., members of the TNF superfamily) and through internal 
responses that deal with stress, such as the ER stress response, autophagy and production of reactive 
oxygen or nitrogenous species (reviewed by [20]). Dying hepatocytes perpetuate the pro-inflammatory 
signal by activating innate immune cells through pattern recognition receptors [6,20,23]. Below we discuss 
briefly the roles of immune cells and central effector molecules that drive inflammation in the liver. 
3.1. What Are the Roles of Resident and Infiltrating Immune Cells in Modulating Liver Inflammation? 
A variety of immune cells contribute to hepatic inflammation, beginning with tissue resident Kupffer 
(resident macrophages) and natural killer cells, followed rapidly by innate cells (neutrophils, monocytes, 
inflammatory macrophages), and then finally by infiltrating natural killer T cells, B cells and T cells 
(reviewed by [6]). Kupffer cells are activated by pathogen- or damage-associated molecular patterns 
(PAMPs and DAMPs). These molecules are not usually expressed in the liver. During processes of sterile 
inflammation and tissue injury with progression to NAFLD, DAMPs are expressed/released by 
hepatocytes to activate receptors on Kupffer and other immune cells [23]. NAFLD is associated with 
changes to the gut microbiome, which can result in the release of PAMPs and damaging bile acids and 
toxins that promote inflammation in the gut and liver (reviewed in [3]). This gut-liver axis hypothesis 
suggests that PAMPs of intestinal origin and DAMPs of liver origin collectively drive hepatic liver 
inflammation and NAFLD [3,23]. In addition, inflammatory signals may arise from hypertrophic 
adipocytes and macrophages in adipose tissue [6]. There is overlap in the inflammatory pathways 
involving PAMPs and DAMPs; those important for the progression of NAFLD include those that involve 
the toll-like receptors, TLR4 and TLR9 [23]. The collective expression of PAMPs/DAMPs results in 
proinflammatory cytokine release (e.g., IL-1β, IL-6, IL-12, IL-18), the recruitment of immune cells and 
further hepatocyte apoptosis [6].  
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3.2. What Are the Central Effector Molecules that Drive Liver Inflammation? 
A shift in the balance of the expression of anti-inflammatory cytokines (e.g., IL-10) towards  
pro-inflammatory cytokines (e.g., TNFα, IL-6) is required for the development of NAFLD [2]. Obesity 
induces TNFα production by adipocytes, facilitating insulin resistance in these cells and increased 
lipolysis. This increases the pool of free fatty acids circulating for uptake in the liver and combined with 
reduced clearance capacity by mitochondria results in the accumulation of triglyerceride droplets in 
hepatocytes (reviewed by [2]). Pro-inflammatory signals may be derived from liver cells or immune 
cells migrating into the liver and include cytokines, reactive oxygen and nitrogenous species, 
chemokines and lipid mediators [6,20]. Many of these mediators are released by keratinocytes or other 
skin cells following dermal exposure to UVR, including TNF [24], IL-6 [25], prostaglandins [26] and 
NO [27]. It is therefore counterintuitive that sunlight could prevent liver inflammation and NAFLD. 
However, there is accumulating evidence that skin exposure to sunlight-derived UVR has potent  
anti-inflammatory effects in the liver, which we detail below.  
4. Evidence for the Control of Hepatic Inflammation by Ultraviolet Radiation:  
Vitamin D-Dependent and Independent Pathways 
4.1. Effects of Phototherapy on Severity of NAFLD 
Phototherapy effectively suppresses the severity of NAFLD in rodent models, through a mechanism 
that is partially dependent on vitamin D [28,29]. Nakano et al. first demonstrated the efficacy of 
phototherapy to curtail the severity of NAFLD in male Lewis rats fed a choline-deficient and  
iron-supplemented L-amino acid (CDAA)-defined diet [28]. The phototherapy was administered for  
12 h/day (unknown dose) from an artificial sunlight source (undefined light spectrum) [28]. It reduced 
hepatocyte apoptosis, inflammation, fibrosis (but not steatosis), insulin/leptin resistance, hepatic and 
circulating triglyceride levels, and the progression to non-alcoholic steatohepatitis (NASH). In addition, 
phototherapy suppressed liver levels of TNFα and TGFβ mRNA and α-smooth muscle actin protein [28]. 
The same phototherapy also reduced liver inflammation and fibrosis in male Zucker fa/fa rats (a  
leptin-deficient model of obesity) [28]. With skin exposure to UVR, circulating 25(OH)D and 
1,25(OH)2D levels increased relative to the control treatment; however, the CDAA diet alone suppressed 
these levels to 20%–30% of their original concentrations. Supplementation of CDAA-fed rats with 
1,25(OH)2D (0.4 μg/kg orally 3 times/week) reduced the severity of liver hepatitis, in a manner similar 
to phototherapy, suggesting that some of its effects were dependent on vitamin D [28]. 
Our studies suggest that UVR has the potential to suppress NAFLD development through vitamin 
D-dependent and -independent mechanisms. In C57Bl/6 male mice fed a high fat diet for 12 weeks, 
chronic sub-erythemal UVR (non-burning, low dose, 1 kJ/m2 UVB twice a week) or erythemal UVR 
(burning, high dose, 4 kJ/m2 UVB once a fortnight) suppressed liver steatosis and lobular ballooning [29]. 
There was no difference in the liver pathology observed with the different doses of UVR [29]. When 
male mice were fed a high fat diet (not supplemented with vitamin D), there was no increase in serum 
25(OH)D levels with UVR [29], which may have been caused by diminished skin levels of  
7-dehydrocholesterol in male mice [30]. Thus, UVR suppressed the severity of NAFLD in a manner that 
was independent of vitamin D. We compared the effects of UVR to dietary vitamin D, and found that 
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while dietary vitamin D3 (~2000 IU/kg added to diet) did significantly alleviate liver steatosis and 
ballooning, UVR was more potent. We also observed significant reductions in circulating TNFα levels 
in mice supplemented with vitamin D [29], but not UVR, suggesting that dietary vitamin D and UVR 
may suppress NAFLD through differing yet complementary mechanisms.  
4.2. Associations between Vitamin D and NAFLD 
The association between serum 25(OH)D concentrations and the presence and/or severity of NAFLD 
has been widely investigated in the last two years, building on a small number of studies published prior 
to 2013 (summarised in Table 1). The majority of these studies were in adults [31–43], with a few 
addressing associations in childhood and adolescence [44–48]. Most used ultrasound to detect  
NAFLD [31,32,35–39,41,42,44,47,48], with some relying on serum alanine transaminase (ALT) as a 
biomarker to detect ‘suspected NAFLD’ [40,45,46]. A few employed the gold-standard method of liver 
biopsy to conclusively diagnose NAFLD [33,34,43]. A wide range of ethnicities has been investigated, 
with studies originating from North America, Europe, Asia and Australia. 
Overall, most observational studies support an inverse association between serum 25(OH)D 
concentrations and NAFLD [31,32,34–44,46–48], independent of potential confounders, such as 
adiposity and insulin resistance. We recently observed a significant inverse association between serum 
25(OH)D concentrations and NAFLD in 17 year-old Western Australian adolescents participating in a 
population-based cohort (n = 718) [44]. A recent meta-analysis of 17 cross-sectional and case-control 
studies of serum 25(OH)D concentrations and NAFLD showed that, compared to controls, NAFLD 
patients were 1.26 times more likely to be vitamin D deficient [49]. 
The reliability of results from observational studies investigating the association between serum 
25(OH)D concentrations and NAFLD may be affected by a number of factors, including the method 
used to detect NAFLD, the type of assay used to measure serum 25(OH)D concentrations, and the 
covariates included in the analyses. Although liver ultrasound provides a useful non-invasive estimate 
of histological hepatic steatosis in large-scale studies [50], it becomes less sensitive when detecting low 
levels of steatosis. Similarly, ALT concentrations are sometimes used as a biomarker to detect 
“suspected NAFLD”, but may be relatively insensitive and nonspecific for NAFLD [51,52]. 
Most observational studies have relied on immunoassay methods, which are highly variable in the 
measurement of serum 25(OH)D concentrations [53,54], and none have reported using an assay that is 
certified to the standard reference method developed by the National Institute of Standards and 
Technology and Ghent University [55]. Not all studies have adequately adjusted for adiposity or season 
of blood collection, and the sample size of many studies has been small and limited to patients at specific 
clinical centres. Importantly, evidence to date is limited to cross-sectional analyses, and the possibility 
of reverse causality cannot be ruled out. Ultimately, although an inverse association between serum 
25(OH)D concentrations and NAFLD is widely reported in the current literature, there is no definitive 
evidence from human studies that supports a causal association between low serum 25(OH)D 
concentrations and the development or severity of NAFLD. 
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Table 1. Associations of circulating 25(OH)D and NAFLD. 
Reference Location 
Sample 
Size 
Percent 
Male 
Age NAFLD Detection Assay Method 
Significant 
Association 
Summary of Findings 
Barchetta et al., 2011 [31] Italy 262 53 Adults Ultrasound DiaSorin LIAISON Inverse 
Low 25(OH)D was associated with NAFLD 
independent of metabolic syndrome, 
diabetes and insulin-resistance profile 
Bril et al., 2014 [33] USA 239 85 18–70 year Biopsy DiaSorin LIAISON None 
Plasma 25(OH)D was not associated with 
insulin resistance, liver fat accumulation or 
severity of NASH 
Dasarathy et al., 2014 [34] USA 187 27 Adults Biopsy 
Standard automatic colorimetric 
methods 
Inverse 
Plasma 25(OHD was an independent 
predictor of NAFLD activity score 
Hao et al., 2014 [35] China 514 100 Adults Ultrasound 
Electrochemiluminescence 
immunoassay (Roche) 
Inverse 
Serum 25(OH)D was inversely associated 
with NAFLD, even in subjects with normal 
total body fat 
Jablonski et al., 2013 [36] USA 1214 26 ≥18 year Ultrasound RIA Inverse 
Compared with matched controls, NAFLD 
patients had significantly lower serum 
25(OH)D 
Kasapoglu et al., 2013 
[37] 
Turkey 613 21 Adults Ultrasound Not reported Inverse 
Low 25(OH)D was associated with NAFLD 
among non-obese subjects 
Kucukazman et al., 2014 
[38] 
Turkey 211 44 Adults Ultrasound RIA Inverse 
Serum 25(OH)D was lower in patients with 
NAFLD compared to those without NAFLD 
Li et al., 2013 [39] China 1248 55 ≥20 year Ultrasound DiaSorin RIA None 
Serum 25(OH)D was not significantly 
associated with the presence of NAFLD 
Liangpunsakul et al., 2011 
[40] 
USA 1287 50 ≥20 year Alanine transaminase RIA Inverse 
Significant inverse association between 
serum 25(OH)D and unexplained elevation 
in alanine aminotransaminase 
Rhee et al., 2013 [41] Korea 6567 100 24–75 year Ultrasound 
Electrochemiluminescence 
immunoassay (Roche) 
Inverse 
Reduced risk for NAFLD with higher serum 
25(OH)D, independent of obesity and 
metabolic syndrome 
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Table 1. Cont. 
Reference Location 
Sample 
Size 
Percent 
Male 
Age NAFLD Detection Assay Method 
Significant 
Association 
Summary of Findings 
Seo et al., 2013 [42] Korea 1081 32 40–69 year Computed tomography DiaSorin LIAISON Inverse 
In subjects with diabetes or insulin 
resistance, low vitamin D status was 
associated with NAFLD, independent of 
visceral obesity 
Targher et al., 2007 [43] Italy 120 67 Adults Biopsy DiaSorin LIAISON Inverse 
Compared with matched controls, NAFLD 
patients had lower serum 25(OH)D 
Bhatt et al., 2013 [32] India 335 71 Adults Ultrasound DiaSorin RIA Inverse 
Low serum 25(OH)D was independently 
associated with NAFLD 
Black et al., 2014 [44] Australia 994 52 17 year Ultrasound LC-MS/MS Inverse 
Lower serum 25(OH)D was significantly 
associated with NAFLD, independent of 
adiposity and insulin resistance 
Katz et al., 2010 [45] USA 1630 52 12–19 year Alanine transaminase DiaSorin RIA None 
No independent association between 
vitamin D status and NAFLD after 
adjusting for obesity 
Malespin et al., 2014 [46] 
USA (Chinese 
American) 
407 51 6–18 year Alanine transaminase Immunochemiluminometric assay Inverse 
Suspected NAFLD was associated with 
lower 25(OH)D after adjusting for  
BMI, sex, triglycerides, total cholesterol, 
LDL, HDL 
Nobili et al., 2014 [47] Italy 73 64 10–15 year Ultrasound HPLC Inverse 
25(OH)D was inversely associated with 
NASH and fibrosis in overweight and obese 
children with NAFLD 
Pirgon et al., 2013 [48] Turkey 87 48 11–15 year Ultrasound DiaSorin LIAISON Inverse 
In obese adolescents, those with NAFLD 
had significantly lower 25(OH)D than those 
without NAFLD 
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An unexplored possibility, which deserves further consideration, is that circulating vitamin D levels 
may represent a proxy for bodily exposure to sunlight [56], a view consistent with the notion that 
individuals with lower 25(OH)D concentrations are more susceptible to disease development. Another 
explanation for the negative associations of vitamin D and NAFLD could relate to an impairment of 
liver function, where inflammation and the disease process itself might curtail the activity of  
25-hydroxylases expressed by hepatocytes, preventing conversion of vitamin D into 25(OH)D. In a 
rodent model of liver inflammation, ligation of bile ducts induced cholestasis, inflammation and fibrosis 
in the liver, and inhibited the activity of vitamin D 25-hydroxlase [57]. Furthermore, expression of the 
25-hydroxylase, CYP2R1 was inversely related to lobular inflammation in patients with NASH [58]. 
These studies suggest that hepatic inflammatory processes may hinder circulating 25(OH)D by affecting 
the hydroxylation of vitamin D in the liver. 
The influence of vitamin D on the development and progression of NAFLD may vary depending on 
the presence of certain genetic polymorphisms. Indeed, genetic variations in vitamin D metabolism have 
been identified and may be associated with liver fibrosis and stiffness [59]. VDR expression in the liver 
and inflammatory cells of chronic liver disease patients is negatively associated with the severity of liver 
histology in both NASH and hepatitis C patients [58]. VDR expression on cholangiocytes was inversely 
correlated with steatosis severity, lobular inflammation and NAFLD score, and expression of CYP2R1 
in hepatocytes of NASH patients correlated strongly with VDR positivity on liver inflammatory cells. 
Adams and colleagues previously observed that a common single nucleotide polymorphism (rs222054) 
in the group specific component gene, which encodes vitamin D binding protein, was associated with 
NAFLD [60]. Based on these current findings, the genetic variation in vitamin D metabolism deserves 
further research with respect to NAFLD. 
4.3. Vitamin D Supplementation and NAFLD 
A number of open clinical trials investigating the effects of vitamin D supplementation on NAFLD 
are currently underway, including three listed at www.clinicaltrials.gov [61] (using vitamin D and  
non-alcoholic fatty liver disease as keywords). One trial will examine the effects of vitamin D3 (2100 IU/day 
orally) compared to placebo on serum ALT in patients with NASH over 48 weeks (NCT01571063). In 
another, the capacity of vitamin D3 (800 IU/day orally) combined with Docosahexaenoic Acid (500 
mg/day orally) to affect NAFLD activity is to be compared with placebo in a pediatric population for 12 
months (NCT02098317). A final trial is determining the efficacy of vitamin D2 (50,000 IU/week for 6 
weeks, and then bi-weekly for 6 months orally) compared to placebo to affect hepatic triglyceride content 
in children and adult patients with type-2 diabetes (NCT02132442). All three have estimated enrolments 
of <70. 
To our knowledge, there is only one published study investigating the effect of vitamin D 
supplementation in patients with NAFLD. Sharifi and colleagues [62] investigated the effect of vitamin 
D supplementation on serum aminotransferases, insulin resistance, oxidative stress and inflammatory 
biomarkers in adult patients with NAFLD in a parallel, double-blind, placebo-controlled study based in 
Iran. Patients were supplemented with 50,000 IU (1250 µg) of vitamin D3 (n = 27) or a placebo (n = 26) 
every 14 days for four months. After adjusting for baseline covariates, including season and body fat 
percentage, vitamin D supplementation improved serum high-sensitive C-reactive protein and serum 
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malondialdehyde concentrations. There was no significant difference between groups in changes in 
serum ALT, aspartate transaminase, alkaline phosphatase and insulin resistance.  
Although the results of Sharifi et al. are relatively unsupportive of a benefit of vitamin D 
supplementation in adults with NAFLD, the study group was small and the intervention limited to four 
months [62]. All of the above-mentioned ongoing clinical trials are aiming to recruit similar or smaller 
group sizes but will test the effects of vitamin D for longer (≥6 months). Furthermore, it will be important 
to compare the clinical effectiveness of vitamin D supplementation with other successful strategies. 
Indeed there is good quality evidence to support the beneficial effect of lifestyle changes that promote 
weight loss (including exercise and diet changes) in reducing the risk of NAFLD [63], and weight loss 
has been shown to improve the histological features of NASH [64]. Interestingly, exercise alone can 
have positive effects on NAFLD independently of weight loss [65]. As much exercise is performed 
outdoors, we suggest that some its benefits may be due to increased sun exposure and the potential 
bioactivity of vitamin D and/or other UV-induced mediators. 
4.4. Mechanisms by Which Vitamin D Could Suppress Liver Pathology 
Vitamin D may prevent liver pathology and the development of NAFLD through the suppression of 
related and potentially interacting pathways that involve hepatocyte apoptosis, liver inflammation and 
fibrosis, oxidative stress, the expression of protective adipokines, and changes to the composition of the 
gut microbiome. 
4.4.1. Vitamin D Inhibits Hepatocyte Apoptosis 
Feeding rats calcitriol (1,25(OH)2D; 1 μg/kg/day, intraperitoneal injection) suppressed the acute rejection 
of liver allografts [66,67]. Vitamin D may have contributed towards allograft survival by inhibiting 
hepatocyte apoptosis, as suggested by its ability to regulate the expression of apoptosis-associated proteins 
in the liver, increasing anti-apoptotic Bcl-2 and Bcl-xL proteins, and decreasing pro-apoptotic Bax and 
Caspase-3 proteins [66]. Calcitriol also inhibited expression of FasL [66], a protein important for the 
ability of cytotoxic T cells to target foreign cells. 
4.4.2. Vitamin D Reduces Liver Fibrosis 
Hepatic stellate cells secrete extracellular matrix, which serves as a scaffold for cellular reconstitution 
and the formation of fibrotic tissue. Active 1,25(OH)2D can directly repress the ability of these cells to 
form type I collagen [68]. When hepatic stellate cells were obtained from morbidly obese patients with 
biopsy-proven NAFLD, liver fibrosis was associated with increased fragmentation of the VDR protein [69]. 
In vitro treatment with 1 μM vitamin D2 suppressed the pro-fibrogenic activity of TGFβ from hepatic 
stellate cells, modifying the expression of the SMAD2 protein [69]. Other studies suggest that vitamin D 
may slow the proliferation of hepatic stellate cells (reviewed by [70]). Together, these observations indicate 
that vitamin D may affect liver fibrosis controlled by hepatic stellate cells through multiple mechanisms. 
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4.4.3. Does Vitamin D Modulate Adipokine Expression? 
Adiponectin is an adipokine (secreted from adipose tissue), which regulates glucose and fatty acid 
oxidation, but may play a protective role in metabolic processes. Adiponectin may suppress liver fibrosis 
by inhibiting secretion of TNFα by hepatic stellate cells [71]. Some studies suggest a positive 
relationship between serum levels of adiponectin and 25(OH)D; however, not all support this link 
(reviewed in [72]). There is also no agreement in results derived from preclinical studies. Phototherapy 
increased circulating adiponectin and 25(OH)D levels in CDAA-fed Lewis rats [28], but dietary vitamin 
D had no effect on adiponectin levels in Sprague-dawley rats fed a ‘westernised diet’ that was high in 
fat and fructose [73] or in mice fed a high fat diet [29]. This might suggest a factor other than vitamin D 
being released by UVR that reduced plasma adipokine levels. Other adipokines, which may contribute 
towards the progression of NAFLD include resistin and leptin [71]. However, like adiponectin, there is 
insufficient evidence, from either preclinical [73,74] or human [75–78] studies to conclusively link their 
expression with the protective effects of vitamin D. 
4.4.4. Vitamin D Alters the Gut Microbiome and Production of Bile Acids 
As highlighted above, PAMPS derived from the gut may contribute towards liver inflammation 
through the liver-gut axis. Roth et al [73] hypothesised that in the absence of vitamin D the gut 
microbiome may change, resulting in enhanced endotoxin exposure and TLR activation, with increased 
expression of TLR-2, -4 and -9 mRNAs observed in the livers of vitamin D-deficient rats fed a 
westernised diet [73]. As we have recently reviewed, vitamin D may induce antimicrobials and promote 
immune tolerance to change the gut microbiome [9]. Other important pathways regulated by vitamin D 
include the metabolism of bile acids by gut microflora and hepatocytes. Bile acids are produced by 
hepatocytes and stored in the gallbladder before release into the gut for fat digestion [3]. Bile acids share 
structural similarity with vitamin D and regulate energy metabolism by interacting with bile acid 
receptors. Loss in the expression of these receptors has been linked with development of NAFLD and 
liver carcinogenesis (reviewed in [3]). Vitamin D may directly suppress the synthesis of bile acids by 
hepatocytes (review in [79]). In addition, changes to the gut microbiome driven by vitamin D deficiency 
may alter the levels or type of bile acids present in the gut. Indeed, the hepatotoxic bile acid, lithochloric 
acid [3], interacts with the vitamin D receptor (VDR), which acts as bile acid receptor and targets the 
acid for degradation [80]. Activation of the VDR by other bile acids or active 1,25(OH)2D [80] may 
enable the degradation of toxic bile acids in the gut and protect from subsequent liver inflammation.  
4.4.5. Vitamin D Suppresses Proinflammatory Cytokines and Mediators of Oxidative Stress 
Increased lobular inflammation and expression of mRNAs encoding the proinflammatory cytokines 
IL-1β, IL-4 and IL-6 was detected in the livers of vitamin D-deficient Sprague-Dawley male rats fed a 
westernised diet [73]. The increased proinflammatory cytokine expression was linked with TLR 
activation, which as detailed above may have reflected changes in the gut microbiome and the release of 
PAMPS. Proinflammatory oxidative stress pathways in the liver may also be regulated by vitamin D. 
Roth et al. observed enhanced expression of heme oxygenase-1 mRNA in the liver of vitamin  
D-deficient rats fed the westernised diet [73]. Orally administered vitamin D3 (12 μg/kg body weight for 
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2 weeks) increased the gene expression of antioxidant defence molecules such as glutathione peroxidase 
and superoxide dismutase in the livers of streptozotocin-induced diabetic rats [81]. In the liver,  
active 1,25(OH)2D may directly suppress the synthesis of proinflammatory cytokines and oxidative 
stress molecules. 
Vitamin D may also regulate inflammation by affecting bile acid transport in the liver. In vitamin D 
deficient mice, the expression of the ileal apical sodium-dependent bile acid cotransporter was reduced 
in the livers of mice with more severe hepatic steatosis and inflammation induced by feeding mice a high 
fat diet [82]. Supplementation of these mice with intramuscular 1,25(OH)2D (5 ng/g body weight, twice 
a week) reversed the effects of vitamin D deficiency on the expression of this bile acid transporter and 
the extent of liver inflammation. In addition, there are various indirect mechanisms, such as hepatocyte 
apoptosis and effects on the gut microbiome, whereby vitamin D targets inflammation (see Figure 2). 
 
Figure 2. Vitamin D may limit the progression of non-alcoholic fatty liver disease through 
multiple, potentially interacting mechanisms. 
4.5. Other UVR-Induced Mediators That Could Suppress Liver Inflammation 
Exposure of skin to UVR induces a suite of mediators, many of which could curtail the severity of 
NAFLD; here, we focus on the potential protective effects of UV-induced NO and heme oxygenase. 
4.5.1. Activation of Dermal Nitric Oxide (NO) by UVR 
NO is an important vasodilator and signaling molecule within the cardiovascular, pulmonary, 
neuronal and immune systems [83]. However, the role that NO plays in modulating liver inflammation 
and hepatotoxicity is incompletely understood (reviewed in [84–87]). Factors that may determine 
whether NO is hepatotoxic or hepatoprotective are how, where and for how long it is produced in the 
liver. NO synthases convert intracellular L-arginine into citrulline and NO. Expression of endothelial 
(e)NOS is constitutive and has beneficial effect on the vasculature, while inducible (i)NOS is generated 
by stress and results in sustained NO production at much higher levels, inducing nitrosative stress 
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(reviewed in [20]). Of relevance here is the ability of 1,25(OH)2D to regulate NO synthesis. Treatment of 
human endothelial cells with 1,25(OH)2D increased the expression of NO through activation of eNOS [88], 
and VDR mutant mice have a lower bioavailability of NO due to reduced eNOS expression in their 
vasculature, leading to endothelial dysfunction and increased arterial stiffness [87]. In contrast, 
1,25(OH)2D inhibited iNOS expression and reduced NO production by LPS-stimulated macrophages 
(RAW264.7 cells) at physiologically-relevant doses [89]. Similarly, 1,25(OH)2D administration 
selectively inhibited expression of the inducible cyclooxygenase isoform, COX-2, an enzyme implicated 
in inflammation, in cultured macrophages [90] and prevented symptoms of allergic asthma by 
suppressing iNOS in rats [91]. These studies suggest that UV-induced 1,25(OH)2D might promote the 
expression of eNOS by endothelial cells to increase constitutive expression of NO, protecting 
hepatocytes from nitrative/oxidative injuries caused by a NO burst invoked by iNOS. Further chemical 
reactions of NO with superoxide form peroxynitrite (ONOO−), and reduce inflammation by 
downregulating COX-2 expression. In addition, an alternate pathway (known as the nitrate-nitrite-nitric 
oxide pathway) for NO production exists, where the anions nitrate and nitrite are reduced back to NO [92]. 
The relative contribution of these pathways to the formation of dermal NO storage forms [27] and hepatic 
protection is currently unclear. 
Skin exposure to UVR mobilizes NO bioactivity from skin, increasing serum nitrite levels within  
20 min of skin exposure, with downstream beneficial suppressive effects on blood pressure [93]. These 
effects were independent of NOS, suggesting an important role for pre-formed cutaneous stores of NO, 
which were detected in the upper layers of the epidermis [93]. Similarly, we observed increased levels 
of NO in the dermis of mice exposed to UVR, and the NO donor, SNAP [29]. In mice fed a high fat diet, 
the extent of liver steatosis and lobular ballooning was significantly reduced by twice-weekly treatment 
with the NO donor, SNAP, or low-dose irradiation with UVR (1 kJ/m2 UVB), with the effects of UVR 
reversed by the NO scavenger cPTIO [29]. The mild blood pressure lowering effects of UVR might be 
explained by the dilation of small blood vessels in the skin secondary to the release of a mediator such 
as NO acting in an autocrine fashion. In contrast, hepatic protection by UVR would demand the 
transduction of bioactivity from the skin to the circulation with subsequent transport to the target organ 
in a paracrine fashion. The precise mechanism by which UVR-induced mobilization of NO bioactivity 
reduces the severity of NAFLD is unknown; however, one means could be through regulation of 
hepatocyte viability. Alternatively, NO may act as an antioxidant [94], leading to the inhibition of 
reactive oxidant species induced lipid oxidation. NO is also known to modulate mitochondrial function 
and biogenesis [95], and as already discussed, hepatocyte death may be promoted by mitochondrial 
dysfunction [22], but further studies are necessary. 
4.5.2. NO-Mediated Upregulation of Heme Oxygenase Expression 
There is uncertainty about the role of HO-1 in the liver and how its expression may affect the severity 
of NAFLD. Hepatic HO-1 protein levels are increased in the liver in patients with NASH relative to 
steatosis-positive controls [96], and there are reports of increased HO-1 mRNA, protein and/or activity 
in the livers of rodents with NAFLD [74,97,98]; yet other preclinical studies do not support these 
findings [99–101]. Interestingly, exposure of skin to UVA radiation increased activity of HO-1 in both 
the skin and liver [102], perhaps indicating a hepato-protective effect for UV-induced HO and control 
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of NAFLD. Indeed, feeding Zucker-Diabetic-Fatty rats heme (twice weekly, 30 mg/kg intraperitoneally) 
upregulated HO-1 activity in the liver, attenuated hepatic inflammatory cytokine expression, hepatocyte 
ballooning and fibrosis [103]. As detailed above, our studies demonstrate that NO is released from dermal 
storage forms by UVR [94]. NO may increase HO-1 expression in a variety of tissues ([104]), There may be 
a role for NO-induced HO-1 in the development of NAFLD, but further mechanistic studies are required. 
5. Conclusions 
Here we review how chronic skin exposure to sunlight-derived UVR may control the development of 
NAFLD. In addition to vitamin D, UVR induces the production of mediators such as NO and HO-1, which 
may contribute towards the protective effects of sunlight through a variety of mechanisms that suppress 
liver inflammation. Chronic skin exposure to UVR may halt the development of NAFLD [28,29], but we 
do not know whether it is possible to intervene; that is, can UVR or its mediators be used to treat already 
established NAFLD? Additional studies are required to test whether the observed associations of 
increased circulating 25(OH)D and positive pre-clinical findings for reduced NAFLD incidence/severity 
can be translated into recommendations for vitamin D supplementation in the clinic. 
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